生物科技板塊更新：力爭上游 (只提供英文版本)

Biotechnology stocks have gotten off to a slow start in 2024, with the S&P Biotechnology Select Industry Index returning just under 4% over the first six months compared to 15% for the S&P 500^® Index.¹

But like an Olympian who underwhelms in the semifinals — only to seemingly come from nowhere to take home gold — the sector could be poised for much stronger performance in the quarters ahead.

The rate cut tailwind

One point of momentum is rate cuts. In late 2023, biotechnology stocks surged as investors bet the Federal Reserve (Fed) would start to trim rates in early 2024. That enthusiasm waned when higher-than-expected inflation prints in the early months of the year caused the Fed to delay.

But with inflation now trending consistently lower and the prospect of a Fed rate cut in September growing, optimism could be returning. In fact, since July 11, when the U.S. Consumer Price Index fell to an annual rate of 3% for the first time in a year, the S&P Biotech index has outperformed the broader equity market (Exhibit 1).

This divergence in returns has precedence. According to analysis done by Redburn Atlantic, in seven of the last eight rate-cutting cycles, the biotech sector has delivered gains both one month and six months after the first rate drop. After 12 months, the sector has outperformed the S&P 500 by an average of 16% (Exhibit 2).

An attractive starting point

Low valuations help support the case for positive returns. Biotechnology valuations have been depressed as a result of a three-year pullback that ended in late 2023. As such, as of mid-July, nearly 130 biotech companies had a negative enterprise value — meaning companies were priced as though any research and development (R&D) would only detract from a firm’s value, not add to it. While that figure is down from a peak of 232 last year, it is still well above pre-downturn levels.²

With a low starting point and investor enthusiasm growing, we think biotech stocks have ample room to run. In the second quarter, the average biotech stock returned 44% following a positive news event, up from 31% during the same quarter the year before. In addition, losses have been more tempered, with the average stock losing only -37% following negative updates.³

創新步伐加快

We expect no shortage of potential catalysts for biotech companies in the months ahead. In the first half of 2024, the Food and Drug Administration approved more than two dozen new drugs, including Imdelltra, a targeted bispecific T-cell engager (TCE) from Amgen for patients with an advanced form of small cell lung cancer. (TCEs are a new type of immunotherapy showing early promise against solid tumors.) Another 41 drugs are expected to be reviewed by the end of the year, including for cancer, schizophrenia, and liver disease, and some could have blockbuster potential (annual sales of $1 billion or more).⁴

This innovation — much of it driven by the sector’s small- and mid-cap companies — is helping fuel a wave of mergers and acquisitions (M&A). During the first half of 2024, 21 transactions were announced, outpacing or equaling total deals done in seven of the last nine years.⁵ While much of the activity has been concentrated in so-called bolt-on acquisitions (deals valued at between $0.5 billion and $2 billion), that could change once the U.S. election and its regulatory impacts become clearer later this year.

In the meantime, companies are finding it easier to raise capital to fund R&D. Indeed, the first half of 2024 was one of the busiest six-month periods on record for equity offerings in biotech, with over $28 billion raised during the period (Exhibit 3).

In our view, these trends indicate demand for biotech’s innovation is alive and well. We also think they suggest it’s only a matter of time — and a few macro factors such as rate cuts and the U.S. election getting sorted out — before biotech could once again come out on top.

Health care industries are subject to government regulation and reimbursement rates, as well as government approval of products and services, which could have a significant effect on price and availability, and can be significantly affected by rapid obsolescence and patent expirations.